Cost-effectiveness of Human Papillomavirus Vaccination in Germany

Overview

Journal Cost Eff Resour Alloc

Publisher Biomed Central

Date 2017 Sep 8

PMID 28878573

Citations 9

Authors

Oliver Damm

Johannes Horn

Rafael T Mikolajczyk

Mirjam E E Kretzschmar

Andreas M Kaufmann

Yvonne Delere

Bernhard Ultsch

Ole Wichmann

Alexander Kramer

Wolfgang Greiner

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to assess the cost-effectiveness of human papillomavirus (HPV) vaccination in addition to the current cervical cancer screening programme in Germany using a dynamic transmission model.

Methods: Based on a mathematical model simulating the transmission dynamics and the natural history of HPV infection and associated diseases (cervical intraepithelial neoplasia, cervical cancer, and genital warts), we estimated the epidemiological and economic consequences of HPV vaccination with both the quadrivalent and bivalent vaccines. In our base case analysis, we assessed the cost-effectiveness of vaccinating 12-year-old girls with a 3-dose schedule. In sensitivity analysis, we also evaluated the use of a 2-dose schedule and assessed the impact of vaccinating boys.

Results: From a health care payer perspective, incremental cost-effectiveness ratios (ICERs) of a 3-dose schedule were €34,249 per quality-adjusted life year (QALY) for the bivalent and €14,711 per QALY for the quadrivalent vaccine. Inclusion of indirect costs decreased ICERs by up to 40%. When adopting a health care payer perspective, ICERs of a 2-dose approach decreased to €19,450 per QALY for the bivalent and to €3645 per QALY for the quadrivalent vaccine. From a societal perspective, a 2-dose approach using the quadrivalent vaccine was a cost-saving strategy while using the bivalent vaccine resulted in an ICER of €13,248 per QALY. Irrespective of the perspective adopted, additional vaccination of boys resulted in ICERs exceeding €50,000 per QALY, except for scenarios with low coverage (20%) in girls.

Conclusions: Our model results suggest that routine HPV vaccination of 12-year-old girls with three doses is likely to be cost-effective in Germany. Due to the additional impact on genital warts, the quadrivalent vaccine appeared to be more cost-effective than the bivalent vaccine. A 2-dose schedule of the quadrivalent vaccine might even lead to cost savings when adopting a societal perspective. The cost-effectiveness of additional vaccination of boys was highly dependent on the coverage in girls.

Citing Articles

Recovery from HPV vaccination deficits caused by the COVID-19 pandemic in Germany: a modeling study of catch-up HPV vaccination among adolescent girls.

Saxena K, Wahner C, Luzak A, Reuter T, Morais E, Chen Y Eur J Pediatr. 2024; 184(1):71.

PMID: 39644333 PMC: 11625053. DOI: 10.1007/s00431-024-05910-y.

Using a Dynamic Model to Estimate the Cost-Effectiveness of HPV Vaccination in Iran.

Hagens A, Sloof A, Janghorban R Vaccines (Basel). 2024; 12(4).

PMID: 38675821 PMC: 11054652. DOI: 10.3390/vaccines12040438.

Factors associated with HPV vaccine hesitancy among college students: A cross-sectional survey based on 3Cs and structural equation model in China.

Chen C, Chen T, Huang M, Huang Y, Zhang L, Li P Hum Vaccin Immunother. 2024; 20(1):2309731.

PMID: 38314749 PMC: 10854271. DOI: 10.1080/21645515.2024.2309731.

Public Health Approach in the Elimination and Control of Cervical Cancer: A Review.

Jallah J, Anjankar A, Nankong F Cureus. 2023; 15(9):e44543.

PMID: 37789997 PMC: 10544705. DOI: 10.7759/cureus.44543.

Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.

Schnitzler L, Evers S, Jackson L, Paulus A, Roberts T BMC Public Health. 2022; 22(1):2180.

PMID: 36434561 PMC: 9701033. DOI: 10.1186/s12889-022-14484-z.

References

Gillison M, Chaturvedi A, Lowy D . HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008; 113(10 Suppl):3036-46. PMC: 6264789. DOI: 10.1002/cncr.23764. View

. HPV and cervical cancer in the 2007 report. Vaccine. 2007; 25 Suppl 3:C1-230. DOI: 10.1016/S0264-410X(07)01183-8. View

Mikolajczyk R, Horn J, Damm O, Kaufmann A, Kretzschmar M . Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections. J Natl Cancer Inst. 2012; 104(2):163. DOI: 10.1093/jnci/djr517. View

Ben Hadj Yahia M, Jouin-Bortolotti A, Dervaux B . Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies. Clin Drug Investig. 2015; 35(8):471-85. DOI: 10.1007/s40261-015-0308-4. View

Kash N, Lee M, Kollipara R, Downing C, Guidry J, Tyring S . Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med. 2015; 4(4):614-33. PMC: 4470159. DOI: 10.3390/jcm4040614. View

Carter J, Koutsky L, Hughes J, Lee S, Kuypers J, Kiviat N . Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000; 181(6):1911-9. DOI: 10.1086/315498. View

Kim J . Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010; 10(12):845-52. PMC: 3982926. DOI: 10.1016/S1473-3099(10)70219-X. View

Horn J, Damm O, Kretzschmar M, Delere Y, Wichmann O, Kaufmann A . Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013; 31(19):2372-80. DOI: 10.1016/j.vaccine.2013.03.006. View

Grulich A, Jin F, Conway E, Stein A, Hocking J . Cancers attributable to human papillomavirus infection. Sex Health. 2010; 7(3):244-52. DOI: 10.1071/SH10020. View

10.

De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G . Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health. 2015; 6:999-1010. PMC: 4262378. DOI: 10.2147/IJWH.S50365. View

11.

Munoz N, Bosch F, Castellsague X, Diaz M, de Sanjose S, Hammouda D . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 111(2):278-85. DOI: 10.1002/ijc.20244. View

12.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

13.

Schobert D, Remy V, Schoeffski O . Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012; 2(1):19. PMC: 3575401. DOI: 10.1186/2191-1991-2-19. View

14.

Klug S, Hukelmann M, Hollwitz B, Duzenli N, Schopp B, Petry K . Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol. 2007; 79(5):616-25. DOI: 10.1002/jmv.20863. View

15.

Soergel P, Makowski L, Schippert C, Staboulidou I, Hille U, Hillemanns P . The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccin Immunother. 2012; 8(2):243-51. DOI: 10.4161/hv.18519. View

16.

Szarewski A, Skinner S, Garland S, Romanowski B, Schwarz T, Apter D . Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013; 208(9):1391-6. PMC: 3789574. DOI: 10.1093/infdis/jit360. View

17.

Hillemanns P, Breugelmans J, Gieseking F, Benard S, Lamure E, Littlewood K . Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008; 8:76. PMC: 2438362. DOI: 10.1186/1471-2334-8-76. View

18.

Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760. View

19.

Canfell K, Barnabas R, Patnick J, Beral V . The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004; 91(3):530-6. PMC: 2409838. DOI: 10.1038/sj.bjc.6602002. View

20.

Gold M, Franks P, McCoy K, Fryback D . Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998; 36(6):778-92. DOI: 10.1097/00005650-199806000-00002. View